INTRODUCTION
Fluorescent protein fusions (FPFs) have been used to address a wide range of questions in individual cells as well as in specific tissues of a particular organism. However, investigators must take extreme care when using FPFs to ensure that the resultant fusion protein is expressed at or close to the endogenous level of the parent protein, and also that it is full length, localizes correctly, and behaves normally once incorporated in the cell. Because the molecular mass of the fluorescent protein (FP) itself is 27 kDa, one must consider the potential effects of placing such a large tag in association with a protein under investigation. This article discusses how these goals can be achieved and provides examples to assist the investigator in designing and implementing experiments using FPFs. 
RELATED INFORMATION

CONSTRUCTING FUSION PROTEINS
Vectors that contain multiple cloning sites are commercially available, and these allow a cDNA or genomic sequence of interest to be placed in-frame at the carboxyl or amino terminus of the FP coding region (e.g., Clontech, MP Biomedicals, and Stratagene). The choice of which vector to use will depend on the location of critical regions of interaction or folding in the protein under study. For example, if a protein of interest has a critical interaction domain at its carboxyl terminus, a logical decision would be to place the FP at the amino terminus of the coding sequence. However, from practical experience, the logical choice is not always the correct choice, and so it may be beneficial to prepare amino-and carboxy-terminal fusions simultaneously and then to assess both fusions for correct localization and associations as described below. In addition to amino-and carboxy-terminal fusions, FPs have been placed internally within a protein's coding sequence, and they have also been used in a bimolecular fluorescence complementation (BiFC) assay for determination of the locations of protein interactions in living cells (Hu et al. 2002) . In the case of internal placement, the mouse major histocompatibility complex class I alle H2Ld was labeled with green fluorescent protein (GFP) placed between the α3 and transmembrane domains of the native protein (Marguet et al. 1999; Rocheleau et al. 2003) . GFP was flanked by amino-and carboxy-terminal linkers, each containing six amino acid residues (PGSIAT and LGMDEL, respectively); for An additional consideration in the development of FPFs is the correct folding of both the protein of interest and the FP. Many investigators have used a linker sequence between the FP and the multicloning site to allow for folding of the FP and the protein of interest without steric hindrance. This approach can also be useful in cases in which the FP may sterically interfere with interactions between the protein of interest and its functional partners. A variety of linker sequences has been used. Expression of actin-GFP in Saccharomyces cerevisiae was accomplished using the normal actin promoter, followed by the entire actincoding sequence, a segment in-frame encoding 10 alanine residues, followed by the GFP sequence (Doyle and Botstein 1996). Other researchers have used 10 glycine-alanine repeats fused to the ATG codon of the GFP sequence (Grava et al. 2000) or a flexible hydrophilic linker (GEGQGQGQGPGRGYAYRS) between the gene of interest and the GFP (Leonhardt et al. 2000) . In addition, vectors are commercially available that contain a six-amino-acid (GGGGGA) flexible linker (MP Biomedicals).
EXPRESSING FUSION PROTEINS
FPFs can be transiently or stably expressed. Transient expression will result in high levels of expression from plasmids that are not integrated into the cellular genome, whereas stable expression, in which genes are integrated into chromosomal DNA and maintained with the use of selectable markers (e.g., G418), can be selected to result in more native levels of expression. Plasmid sequences can be introduced into cells by electroporation, chemical treatment (calcium phosphate [CaPO 4 ]) using various lipofection reagents purchased as kits (e.g., FuGENE 6 from Roche Applied Science, Lipofectamine 2000 from Invitrogen, and DOTAP from Biontex Inc.), retroviral transformation, or microinjection. Regardless of the approach taken, optimal conditions must be determined for individual cell types. We routinely use electroporation and have worked out conditions such that FPFs can be detected in human U2OS cells as soon as 2 h post-electroporation using a Bio-Rad Gene Pulser II (or equivalent) operating at 170 V, 950 μF (Janicki et al. 2004) , thereby allowing for low levels of protein expression. The level of expression of a particular fusion protein can vary depending on the amount of plasmid DNA transfected, the promoter strength, and the time of expression. These conditions should be optimized to obtain a low level of expression that correctly mimics the localization of the native protein and provides enough fluorescence signal to perform time-lapse studies.
Although transient expression is quick and can provide informative results, in many cases, it is beneficial and/or essential to develop stable cell lines expressing the fusion protein of interest. In addition to providing more native levels of expression, the individual clones can be generated from single cells, the integration site of the plasmid can be mapped, and the copy number can be determined. Moreover, because every cell in the population is expressing the fusion protein, cell cycle analyses and biochemical fractionation are significantly easier to accomplish. The protocol Transfection of Mammalian Cells with Fluorescent Protein Fusions (Spector and Goldman 2010), which was developed by Margaret Wheelock (University of Nebraska) and modified by Paula Bubulya (Wright State University), can be used for the development of stable cell lines expressing FPFs.
DEVELOPMENT OF STABLE MAMMALIAN CELL LINES EXPRESSING FLUORESCENT PROTEIN FUSIONS
Before beginning the protocol Transfection of Mammalian Cells with Fluorescent Protein Fusions (Spector and Goldman 2010), the following issues must be considered, and the reagents should be prepared and organized.
DNA for Transfection
Prepare ., QIAGEN) . The amount of DNA used in transfection varies depending on the transfection method used and should be optimized by transient transfection to obtain appropriate levels of protein expression prior to attempting stable transfection.
Antibiotic for Selection of Stable Clones
The appropriate concentration of antibiotic used for selection purposes will vary depending on the antibiotic and the cell type being investigated. Before beginning the stable transfection, determine the amount of antibiotic that will kill most of the cells in a dish within 2-4 d. Some antibiotics act quickly (puromycin), whereas others take several days (Geneticin/G418).
Screening Protocol
Plan ahead. Stable clones will need to be screened, and frozen stocks will have to be prepared for ~4-8 wk after transfection. For FPFs, cells will be scored for expression by fluorescence microscopy. Because it is common to obtain clones that express a truncated construct, positive clones should be further screened by immunoblotting to verify the correct size of the fusion construct.
Cells for Transfection
Split the cells 2 d prior to the day of transfection to stimulate cell growth. Plate cells for transfection on the day before the transfection. For electroporation, aim for an 80% confluent dish of cells to use the following day. For transfection protocols that require attached cells, such as CaPO 4 or lipid-mediated transfection, aim for a 10%-20% or 20%-40%, respectively, confluent dish of cells to use the following day. When transfecting cells that grow very rapidly, such as baby hamster kidney (BHK) cells, use fewer cells per dish.
